Repeatability of Quantitative 18F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
FIGURE 1.
Test–retest variability of SUV and TBR variants. Significant differences have been indicated with asterisk (Holms-Bonferroni–corrected P values). Differences in repeatability between SUVs and between TBRs were not significant.
Download figure
Open in new tab
Download powerpoint
FIGURE 2.
Bland–Altman plots of lesion-level metrics: SUV_peak (A), peak TBR (B), volume (C), and TBR TLU (D). y-axis in C and D were log-scaled for visual interpretation.
Download figure
Open in new tab
Download powerpoint
FIGURE 3.
Bland–Altman plots of patient-level metrics TTV, SUV TTB, and TBR TTB. y-axes were log-scaled for visual interpretation.

TABLE 1

Patient and Scan Characteristics of Patients Included in Repeatability Analysis (n = 10)

Characteristic	Data
Age (y)	74 (61–79)
Initial Gleason score	8 (6–9)
PSA at PET/CT (ng/mL)	9 (1–2,796)
Length (cm)	178 (168–192)
Weight (kg)	88 (68–94)
PCa stage
Primary metastatic	2 (20.0%)
Biochemically recurrent	3 (30.0%)
Castration-resistant	5 (50.0%)
Analyzed lesion type
Bone	21 (58.3%)
Lymph node	12 (33.3%)
Intraprostatic	3^* (8.3%)
Androgen deprivation at PET/CT	7 (70.0%)
Prior docetaxel	3 (30.0%)
Injected activity (MBq)
Test	317 (280–331)
Retest	313 (254–341)
Uptake time (min)
Test	120 (118–153)
Retest	122 (111–149)
Test–retest difference^†
Injected activity (MBq)	28 (8–63)
Uptake time (min)	3 (0–22)

↵* Differences were not significant (P > 0.05).
↵† 2 intraprostatic foci in 1 patient.
Qualitative data are numbers followed by percentages in parentheses; continuous data are median followed by range in parentheses.

TABLE 2

Descriptive Data of Lesion and Patient-Based Uptake Metrics on Test and Retest Scans

TABLE 3

Repeatability of Lesion- and Patient-Based ¹⁸F-DCFPyL Uptake Metrics